Tuesday, May 09, 2017 7:48:26 PM
CP you have to stratify numbers for Exosome
reminds me, in reply to your 2 1/2 markets, been there - done it
(courtesy of the cheynew compilation today)
swg_tdr
Tuesday, 04/25/17 11:08:10 AM
Re: swg_tdr post# 295706
Post # 295707 of 295714
1. EXOSOME $67 BILLION SALES WORLDWIDE (END-POINT PRICING)
Exosome BINARY blood test Base market parameters, Early detection annual & survivor monitor
Population size/geographical/market characteristics:
USA 324.3millon (current estimate; and 281.4m, Yr 2000 census)
stratified ages 35 to 64 years 197.1m (2016 estimate) is the key sector, at 33%, BASE 65.0m (read-outs a year)
age 65 to 74, 18.4m, assume 50% not able or too poor, BASE 9.2 m (Medicare paid)
cancer patient families @ 3.4m (1.7m new cases, 0.6m deaths/yr), EARLY BASE 3.4million tests
"add -- follow-up if stable or progression" annual check-up of survivors @ 1.1m
cancer survivors 1.1 per year times 8 (?), BASE 8.8m (with 3 tests per year, 26m equiv?)
cancer stats per American Cancer Society, 2017, note-- four major cancers only
"early trendsetters" IF adequately promoted by partner
corporate "key management medicals", mandatory, introductory target 2.0million (assumed)
entertainment sector, entrepreneurs, professional groups, alumni groups, introductory 15.0m (guess)
E U Europe Population (including 64million of UK)
508million; ages 35 to 74 at 228million (appx), at 80% compliant, TARGET 182million tests
cancer patient families (3.7m new cases, 1.9m deaths/yr), BASE 7.4million tests
per statistica, statistics portal, 2016
cancer survivors 1.8m per year, times 8 (?), BASE 14.4m (with 3 tests per year, 43m equiv?)
JAPAN
127million, ages 35 to 74 at 89m (?), and at 90%, TARGET 80million
AUSTRALIA, S. KOREA, CANADA
at 23, 50 and 35million respectively, total 108million, ball park TARGET 65million
TOTAL ANNUAL TESTS WORLDWIDE 448 MILLION, AT $150 PER, OR $67.2BILLION
FOR EARLY DETECTION AND SURVIVOR MONITORING
THE EARLY BASE IN THE USA (trendsetters and cancer families) $3.1 BILLION PER YEAR
next
How much of this $67Billion annual ultimate potential will revert to Peregrine? and it will not be astronomical even in this "first in market coupe" preventive early detection and post-treatment monitoring sector
How might a break-down of a NSCLC patient billings inform us of the current billings for tests in NSCLC sector? And hence, what are the types of diagnostics in the USA Oncology market that could add up to $20billion now and can Exosome displace much, or only supplement within this $107billion total cancer treatment billed maket (no way $200B here)
Best,
N
PS So Peregrine management, peel this market by geography and do the first deal already -- auction by geographic areas, to cut the consumer deal part for preventive early detection now.
reminds me, in reply to your 2 1/2 markets, been there - done it
(courtesy of the cheynew compilation today)
swg_tdr
Tuesday, 04/25/17 11:08:10 AM
Re: swg_tdr post# 295706
Post # 295707 of 295714
1. EXOSOME $67 BILLION SALES WORLDWIDE (END-POINT PRICING)
Exosome BINARY blood test Base market parameters, Early detection annual & survivor monitor
Population size/geographical/market characteristics:
USA 324.3millon (current estimate; and 281.4m, Yr 2000 census)
stratified ages 35 to 64 years 197.1m (2016 estimate) is the key sector, at 33%, BASE 65.0m (read-outs a year)
age 65 to 74, 18.4m, assume 50% not able or too poor, BASE 9.2 m (Medicare paid)
cancer patient families @ 3.4m (1.7m new cases, 0.6m deaths/yr), EARLY BASE 3.4million tests
"add -- follow-up if stable or progression" annual check-up of survivors @ 1.1m
cancer survivors 1.1 per year times 8 (?), BASE 8.8m (with 3 tests per year, 26m equiv?)
cancer stats per American Cancer Society, 2017, note-- four major cancers only
"early trendsetters" IF adequately promoted by partner
corporate "key management medicals", mandatory, introductory target 2.0million (assumed)
entertainment sector, entrepreneurs, professional groups, alumni groups, introductory 15.0m (guess)
E U Europe Population (including 64million of UK)
508million; ages 35 to 74 at 228million (appx), at 80% compliant, TARGET 182million tests
cancer patient families (3.7m new cases, 1.9m deaths/yr), BASE 7.4million tests
per statistica, statistics portal, 2016
cancer survivors 1.8m per year, times 8 (?), BASE 14.4m (with 3 tests per year, 43m equiv?)
JAPAN
127million, ages 35 to 74 at 89m (?), and at 90%, TARGET 80million
AUSTRALIA, S. KOREA, CANADA
at 23, 50 and 35million respectively, total 108million, ball park TARGET 65million
TOTAL ANNUAL TESTS WORLDWIDE 448 MILLION, AT $150 PER, OR $67.2BILLION
FOR EARLY DETECTION AND SURVIVOR MONITORING
THE EARLY BASE IN THE USA (trendsetters and cancer families) $3.1 BILLION PER YEAR
next
How much of this $67Billion annual ultimate potential will revert to Peregrine? and it will not be astronomical even in this "first in market coupe" preventive early detection and post-treatment monitoring sector
How might a break-down of a NSCLC patient billings inform us of the current billings for tests in NSCLC sector? And hence, what are the types of diagnostics in the USA Oncology market that could add up to $20billion now and can Exosome displace much, or only supplement within this $107billion total cancer treatment billed maket (no way $200B here)
Best,
N
PS So Peregrine management, peel this market by geography and do the first deal already -- auction by geographic areas, to cut the consumer deal part for preventive early detection now.
